Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands
about
Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profilingEpithelial tumours of the lacrimal gland: a clinical, histopathological, surgical and oncological surveyManagement of salivary gland carcinomas - a reviewParticular aspects in the cytogenetics and molecular biology of salivary gland tumours - current review of reportsA Phase II study of Dovitinib in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma.Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials.Targeting the disordered C terminus of PTP1B with an allosteric inhibitorA phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma.Combined treatment of adenoid cystic carcinoma with cetuximab and IMRT plus C12 heavy ion boost: ACCEPT [ACC, Erbitux® and particle therapy].Multi-institutional retrospective study of mucoepidermoid carcinoma treated with carbon-ion radiotherapySustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine.Targeting the EGFR signaling pathway in cancer therapy.Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysisRadioImmunotherapy for adenoid cystic carcinoma: a single-institution series of combined treatment with cetuximab.A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma.Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trialA phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).The molecular pathogenesis of head and neck cancer.Small molecule inhibitors of the host cell COX/AREG/EGFR/ERK pathway attenuate cytomegalovirus-induced pathogenesisA unifying gene signature for adenoid cystic cancer identifies parallel MYB-dependent and MYB-independent therapeutic targets.Human Epidermal Growth Factor Receptor 2 (HER2/neu) in Salivary Gland Carcinomas: A Review of Literature.Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignanciesLoss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancerOutcomes and prognostic factors in modern era management of major salivary gland cancer.Metastatic Salivary Gland Tumors: A Single-Center Study Demonstrating the Feasibility and Potential Clinical Benefit of Molecular-Profiling-Guided Therapy.Parotid carcinoma: Current diagnostic workup and treatment.Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinomaPrioritizing phase I treatment options through preclinical testing on personalized tumorgraft.The mutational landscape of adenoid cystic carcinomaSystemic therapies for recurrent and/or metastatic salivary gland cancers.Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas.Salivary gland cancers: current treatments, molecular characteristics and new therapies.New agents in the treatment for malignancies of the salivary and thyroid glands.Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial.No incidence of BRAF mutations in salivary gland carcinomas--implications for anti-EGFR therapies.Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinibCetuximab in the treatment of metastatic mucoepidermoid carcinoma of the salivary glands: a case report and review of literature.Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond.Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study.
P2860
Q26781643-B689F037-98C7-4FE3-BAC9-05BCB60C6736Q27025842-0F174779-4E36-4EFF-9A23-7F7C52EA95ACQ28069083-8DF1E7B5-FA39-4138-93DE-7F6F4CBA36F6Q28079483-550999C4-FEC4-4607-92EA-34794FC91333Q30252721-BDBCDEFD-C19F-486A-8E6B-E1C198A5CDFAQ30301145-3F4EEDB5-6893-41DD-B001-987974E4BA69Q33774262-21FE1AE9-993C-43F8-BBBC-4152864A8843Q33779308-4BAC3F71-F3C4-4D43-917C-109E83655FD0Q33820302-76FA5D65-E869-43D7-9EC1-2136DF255511Q33873306-70787558-687B-446C-A64C-12190BF45E40Q33931069-1CA0353F-90DF-449C-86E4-A54FA7AA65B8Q34246558-7082874B-05B6-4697-81E5-AD352EB5A0D7Q34272887-3C3B32C6-7646-4095-92DB-F138FE583B56Q34331751-D2F4D9FE-F5F1-42FE-8232-22604A8FF8D3Q34491238-87AC4B17-F5A0-4180-BED5-E1C6C512956DQ34848294-ABE2EE6F-7C0A-4691-BB16-8CF7D2307F69Q35103364-E19E7BA4-CCAA-4E7A-AAB2-2F2D2E08DFAEQ35111736-BFA82EF3-FB7C-4584-BD8B-5288C3609D07Q35115725-591B3F56-E8C1-451F-8C73-DB310D2F51F6Q35149666-8E671F1C-7432-4D69-AF10-C88737396AFAQ35230643-4D95042F-C4E5-4D61-BAF3-98AF6AE54670Q35290247-40C62029-B7D3-48C8-93D5-67B5FFA0BAB7Q35764742-7977C1A2-2A80-428D-906A-508FF3E59057Q35889915-E170946E-49D5-4996-B397-5DFB0A94962CQ36095613-59AD3276-3363-4B92-A1CA-B99787ADE494Q36170033-A69874B1-526D-49B3-9768-FE72EE7F7805Q36755219-1209FFD8-282E-4466-BADF-0048E6ED55F3Q36920470-A5E9FE91-3B44-442C-BF00-4FFBF4DE9CA0Q37003447-F7CB5BB2-4095-4A87-BE04-EC0789FF3461Q37118940-36F10479-3F68-4E87-9EC0-E95383220569Q37119716-2BC6556D-C2F8-497D-AFB7-B72F6295F2B3Q37123445-1FEE81A4-8E03-4292-8131-B1E82959CEBFQ37134463-B7DFBDF6-C89D-44DD-868D-F61001CF3455Q37137859-3E8B700F-7A80-43B9-A5DC-6890B31C3BDFQ37185867-A2CBFEE8-DEC7-435C-8B3E-CCDB30F9169DQ37235203-99ED6A46-982A-40DB-811A-C80BDDEECC39Q37265167-5F0ADDE3-FD15-4B8F-9129-285D81A88145Q37282841-5881D571-7897-42CF-9698-EAF7807FA3D2Q37333041-76AE617E-99B7-46D5-88C1-16FB8131DF5CQ37364638-E00EFB17-4D61-4C38-B426-71D9EB0E9487
P2860
Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands
description
im September 2007 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 2007
@uk
name
Phase II Study of Lapatinib in ...... Tumors of the Salivary Glands
@en
Phase II Study of Lapatinib in ...... Tumors of the Salivary Glands
@nl
type
label
Phase II Study of Lapatinib in ...... Tumors of the Salivary Glands
@en
Phase II Study of Lapatinib in ...... Tumors of the Salivary Glands
@nl
prefLabel
Phase II Study of Lapatinib in ...... Tumors of the Salivary Glands
@en
Phase II Study of Lapatinib in ...... Tumors of the Salivary Glands
@nl
P2093
P50
P356
P1476
Phase II Study of Lapatinib in ...... Tumors of the Salivary Glands
@en
P2093
Eric Winquist
Eric X. Chen
Gregory R. Pond
Ian Lorimer
Janet E. Dancey
Lillian L. Siu
Manijeh Daneshmand
Mark Agulnik
Roger B. Cohen
P304
P356
10.1200/JCO.2007.11.8612
P407
P577
2007-09-01T00:00:00Z